Impact of Coronavirus Disease 2019 on Prognosis and Treatment Strategies in Patients with Hematological Malignancy--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 645-648, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-928769
ABSTRACT
Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide since outbreak in December 2019, and become a global public health crisis. Patients with hematological malignancy concurrently infected with COVID-19 are often associated with severe even fatal complications, due to low basic immune function, high intensity of chemotherapy and radiotherapy, and slow immune reconstruction post hematopoietic stem cell transplantation, and their treatment strategies, such as anti-infective therapy, blood transfusion, and the use of granulocyte colony stimulating factor need to be adjusted. The characteristics of patients, chemotherapy, hematopoietic stem cell transplantation, and other clinical factors may affect the prognosis of patients with hematological malignancy concurrently infected with COVID-19. Herein, the latest research progress is reviewed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Granulocyte Colony-Stimulating Factor
/
Hematopoietic Stem Cell Transplantation
/
Hematologic Neoplasms
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS